NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0.741. It has been cited 22 times, with 17 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.271
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 17 citers.
NIH HHS
Grant: S10 OD024977
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 1S10OD024977-01
NovaSeq6000
FWCI
1.67
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization
Additional file 1 of Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization